Abstract OT1-02-05: Phase II clinical trial of neratinib in patients 60 and older with HER2 over-expressed or mutated breast cancer: Trial design considerations for older adults

Mapping Intimacies ◽

10.1158/1538-7445.sabcs16-ot1-02-05 ◽

2017 ◽

Author(s):

Y Yuan ◽

S Blanchard ◽

D Li ◽

J Mortimer ◽

J Waisman ◽

...

Keyword(s):

Breast Cancer ◽

Older Adults ◽

Clinical Trial ◽

Phase Ii ◽

Trial Design ◽

Phase Ii Clinical Trial ◽

Cancer Trial ◽

Design Considerations

Download Full-text

Extending the two‐stage single arm phase II clinical trial design to the delayed response scenario

Pharmaceutical Statistics ◽

10.1002/pst.2171 ◽

2021 ◽

Author(s):

Bo Chen ◽

Xing Zhao ◽

Juying Zhang

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Trial Design ◽

Clinical Trial Design ◽

Phase Ii Clinical Trial ◽

Delayed Response ◽

Download Full-text

Phase II Clinical Trial Design: Methods in Translational Research from the Genitourinary Committee at the Eastern Cooperative Oncology Group: Table 1.

Clinical Cancer Research ◽

10.1158/1078-0432.ccr-05-1136 ◽

2006 ◽

Vol 12 (7) ◽

pp. 1966-1969 ◽

Author(s):

Robert Gray ◽

Judith Manola ◽

Scott Saxman ◽

John Wright ◽

Jan Dutcher ◽

...

Keyword(s):

Clinical Trial ◽

Translational Research ◽

Phase Ii ◽

Trial Design ◽

Eastern Cooperative Oncology Group ◽

Clinical Trial Design ◽

Design Methods ◽

Phase Ii Clinical Trial ◽

Download Full-text

The effects of heterogeneity on Simon Phase II clinical trial design operating characteristics

Open Access Journal of Clinical Trials ◽

10.2147/oajct.s10470 ◽

2010 ◽

pp. 107 ◽

Author(s):

Christopher Barnes

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Trial Design ◽

Clinical Trial Design ◽

Phase Ii Clinical Trial ◽

Operating Characteristics

Download Full-text

Biomarker-based Bayesian randomized phase II clinical trial design to identify a sensitive patient subpopulation

Statistics in Medicine ◽

10.1002/sim.6209 ◽

2014 ◽

Vol 33 (23) ◽

pp. 4008-4016 ◽

Author(s):

Satoshi Morita ◽

Hideharu Yamamoto ◽

Yasuo Sugitani

Keyword(s):

Clinical Trial ◽

Phase Ii ◽

Trial Design ◽

Clinical Trial Design ◽

Phase Ii Clinical Trial ◽

Randomized Phase Ii

Download Full-text

Abstract P4-01-03: HDACi (vorinostat) in metastatic breast cancer to restore sensitivity to ER-directed (AI) therapy: A phase II clinical trial with FES imaging correlates

10.1158/0008-5472.sabcs13-p4-01-03 ◽

2013 ◽

Author(s):

HM Linden ◽

BF Kurland ◽

JM Link ◽

A Novakova ◽

X Chai ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Metastatic Breast Cancer ◽

Phase Ii ◽

Metastatic Breast ◽

Phase Ii Clinical Trial

Download Full-text

Abstract P1-14-06: Everolimus effect on hematologic parameters in a phase II clinical trial for metastatic estrogen receptor (ER) positive breast cancer

10.1158/0008-5472.sabcs13-p1-14-06 ◽

2013 ◽

Author(s):

A Chen ◽

L Chen ◽

E Romond ◽

V Kadamyan ◽

M Stevens ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Estrogen Receptor ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Er Positive ◽

Positive Breast Cancer

Download Full-text

Abstract CT302: A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic or recurrent breast cancer patients with triple negative disease

10.1158/1538-7445.am2014-ct302 ◽

2014 ◽

Author(s):

Stacy Cowherd ◽

Susan Melin ◽

Steven Akman ◽

John Cole ◽

Julia Lawrence

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Cancer Patients ◽

Phase Ii ◽

Triple Negative ◽

Recurrent Breast Cancer ◽

Phase Ii Clinical Trial ◽

Weekly Paclitaxel ◽

Breast Cancer Patients ◽

Recurrent Breast

Download Full-text

Abstract OT1-05-02: A phase II clinical trial of the combination of pembrolizumab and selective androgen receptor modulator GTx-024 in patients with advanced androgen receptor positive triple negative breast cancer

10.1158/1538-7445.sabcs17-ot1-05-02 ◽

2018 ◽

Author(s):

Y Yuan ◽

P Frankel ◽

T Synold ◽

P Lee ◽

S Yost ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Androgen Receptor ◽

Phase Ii ◽

Triple Negative Breast Cancer ◽

Triple Negative ◽

Phase Ii Clinical Trial ◽

Selective Androgen Receptor Modulator ◽

Receptor Modulator

Download Full-text

P4-016: MCLENA-1: A PHASE II CLINICAL TRIAL FOR THE ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LENALIDOMIDE IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMER'S DISEASE; TRIAL DESIGN AND RATIONALE

Alzheimer s & Dementia ◽

10.1016/j.jalz.2019.06.3675 ◽

2019 ◽

Vol 15 ◽

pp. P1279-P1279

Author(s):

Boris Decourt ◽

Nadia Fulkerson ◽

Alana Burns ◽

Garam Lee ◽

Tessa St Rose ◽

...

Keyword(s):

Alzheimer’S Disease ◽

Alzheimer's Disease ◽

Clinical Trial ◽

Cognitive Impairment ◽

Mild Cognitive Impairment ◽

Phase Ii ◽

Trial Design ◽

Phase Ii Clinical Trial

Download Full-text

A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer

Breast Cancer Research and Treatment ◽

10.1007/s10549-020-05928-4 ◽

2020 ◽

Author(s):

Otto Metzger Filho ◽

Anita Giobbie-Hurder ◽

Nancy U. Lin ◽

Meredith Faggen ◽

Steven Come ◽

...

Keyword(s):

Breast Cancer ◽

Clinical Trial ◽

Adverse Events ◽

Cancer Patients ◽

Phase Ii ◽

Phase Ii Clinical Trial ◽

Breast Cancer Patients

Download Full-text